Hyperbaric Oxygen Therapy: New Hope for PTSD, Depression & Anxiety?

For decades, hyperbaric oxygen therapy (HBOT) has been a mainstay in emergency medicine, utilized for conditions like carbon monoxide poisoning and decompression sickness. But a growing body of research suggests this treatment—involving breathing pure oxygen at elevated pressure—may offer benefits beyond physical ailments, potentially impacting mental health conditions like posttraumatic stress disorder (PTSD), depression, and anxiety. The emerging science centers on HBOT’s ability to not just increase oxygen levels in the blood, but to actively reshape brain function.

What Does Hyperbaric Oxygen Therapy Entail?

HBOT involves a patient breathing 100% oxygen inside a pressurized chamber, typically at 1.5 to 3 times normal atmospheric pressure. This increased pressure allows a significantly higher concentration of oxygen to dissolve directly into the blood plasma, bypassing the usual reliance on red blood cells for oxygen transport. This floods tissues with oxygen, but the benefits extend far beyond simple oxygenation.

Research indicates HBOT can influence brain plasticity and cellular function. It can restore energy production in cells with impaired mitochondria – often called the “powerhouses” of cells – which are crucial for generating ATP, the body’s primary energy source. Mitochondria also produce reactive oxygen species (ROS), molecules that play a role in immune defense. HBOT stimulates the growth of new neurons and blood vessels (angiogenesis), reduces neuroinflammation, and promotes the formation of new synapses, the connections between neurons that are vital for learning and memory.

Researchers have identified a phenomenon called the hyperoxic-hypoxic paradox, where cycling between high and normal oxygen levels creates a temporary, perceived oxygen deficiency. This triggers the brain’s repair mechanisms and promotes neuroplastic changes, essentially reshaping brain structure and function. A study published in Frontiers in Neurology details this process and its potential implications for neurological and psychiatric conditions.

Promising Results in Posttraumatic Stress Disorder

Some of the most compelling evidence for HBOT’s potential in psychiatric care comes from studies on PTSD, particularly in patients who haven’t responded to conventional treatments. Veterans who had found little relief from antidepressants, antianxiety medications, exposure therapy, and Eye Movement Desensitization and Reprocessing (EMDR) participated in a clinical trial evaluating HBOT. The results showed not only improvements in PTSD symptoms but also measurable changes on brain scans associated with improved functioning.

This wasn’t an isolated finding. A 2024 review in Frontiers in Neurology analyzed multiple studies involving both military personnel and civilians, men and women, and individuals with PTSD stemming from diverse traumas – combat, sexual assault, and other sources. The review consistently found symptom improvement across these varied populations. Importantly, the benefits appeared linked to the underlying biological mechanisms of PTSD, rather than the specific traumatic event itself. The review also indicated a dose-response relationship, suggesting that more HBOT sessions correlated with better outcomes.

Exploring HBOT for Depression and Anxiety

The evidence supporting HBOT for depression and anxiety is also encouraging, though still developing. In stroke patients experiencing depression, HBOT has shown promise in improving mood by repairing damaged blood vessels and reducing brain inflammation. A study comparing HBOT to psychotherapy in patients with depression and anxiety following spinal cord injury found comparable improvements in mood and anxiety levels in both groups. This research, published in 2017, suggests HBOT could be a viable alternative or adjunct to traditional therapies.

Potential Benefits for Post-COVID Conditions

The neuropsychiatric symptoms associated with long COVID – including anxiety, depression, cognitive impairment, sleep disturbances, and PTSD-like symptoms – share similarities with the neuroinflammatory and vascular problems that HBOT is known to address. Early results from HBOT treatment in post-COVID patients have been positive. A double-blind, randomized trial demonstrated significant improvements in psychiatric symptoms, cognitive function, energy levels, sleep quality, and pain in patients receiving HBOT compared to a placebo control group. Notably, a follow-up study revealed that these benefits persisted for at least one year, offering hope for long-term relief for chronically ill patients.

Cognitive Enhancement Through HBOT

HBOT may also improve cognitive function, addressing impairments in memory, attention, executive function, and processing speed often associated with PTSD, depression, and anxiety. A 2025 study found improvements in neurobehavioral symptoms in patients with post-brain-injury symptoms treated with HBOT, compared to control groups.

Important Considerations and Limitations

Although these early studies are promising, it’s crucial to acknowledge that the evidence base for HBOT as a psychiatric treatment is still evolving. Larger, more rigorous studies are needed to confirm these findings and establish optimal treatment protocols. For individuals with depression and anxiety not linked to underlying neurological conditions like traumatic brain injury or stroke, the benefits of HBOT remain largely theoretical.

HBOT is not without potential risks. Mild side effects can include ear discomfort or injury, though these are typically temporary. Rarely, oxygen toxicity can occur. Claustrophobia can also be a concern for some individuals. HBOT is a time-consuming and expensive treatment. A typical course involves 20-40 sessions, and the U.S. Food and Drug Administration has not yet approved HBOT for psychiatric indications, meaning insurance coverage is unlikely. Costs can range from $150 to $650 per session, totaling $3,000 to $26,000 for a complete course of treatment.

Looking Ahead: The Future of HBOT in Mental Healthcare

The exciting aspect of HBOT in the context of psychiatric disorders is its potential to address common underlying mechanisms across various conditions. These may include neuroinflammation, disrupted blood flow to the brain, and mitochondrial dysfunction. As neuroimaging technologies advance and larger clinical trials are conducted, we will gain a clearer understanding of who will benefit most from HBOT, what treatment protocols are most effective, and how this therapy can be integrated into broader psychiatric care. For individuals who have exhausted other treatment options, the results seen so far are compelling and warrant further investigation.